Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 June 2025 | Story Tshepo Tsotetsi | Photo Supplied
Dr Herkulaas Combrink
Dr Herkulaas Combrink is representing UFS in a new international research project that aims to improve how evidence is used in public health policymaking.

Dr Herkulaas Combrink, a senior lecturer in the Faculty of Economic and Management Sciences (EMS) at the University of the Free State (UFS), is representing the university in a new international research project that aims to improve how evidence is used in public health policymaking.

Dr Combrink, who is also a co-director of the Interdisciplinary Centre for Digital Futures (ICDF), has been selected as one of the principal investigators in a newly funded project supported by the UK’s International Science Partnerships Fund under the Evidence-Informed Policymaking Programme. Running from April 2025 to March 2026, the project – titled Integrating Evidence for Contextualised Public Health Policy: Lessons from South Africa – explores how different types of evidence can be used more effectively in shaping public health policy. The international collaboration includes researchers from the Centre for Philosophy of Epidemiology, Medicine and Public Health, which is a collaboration between Durham University and the University of Johannesburg; as well as Durham’s Centre for Humanities Engaging Science and Society.

 

From the Free State to global impact

For Dr Combrink, being part of this collaboration highlights the important work being done in the faculty and ICDF that is reaching beyond borders. 

“It’s important to showcase the impact we are making from the Free State that leads to global outcomes,” he said.

The project aims to evaluate an evidence mapping framework to determine how model-based projections and social listening reports can be more effectively integrated and contextualised for policymaking.

“These are two very different data types,” he explained. “The value lies in demonstrating how to apply the framework to different contexts for evidence-based mapping.”

Dr Combrink brings extensive expertise to the team, having worked on both disease modelling and risk communication during South Africa’s COVID-19 response. He was involved in national and provincial social listening initiatives, and used high-frequency social media data to track the spread of misinformation, often referred to as the ‘infodemic.’ 

“We’ve built up enough data within ICDF and EMS to support this study,” he noted.

The goal is not just theoretical. A key outcome of the project is engaging directly with policymakers to refine modelling and risk communication strategies for future pandemics. 

“This will help us to engage with the various departments of health to assist with improving modelling and risk communication work for better social behavioural change,” he explained.

According to Prof Brownhilder Neneh, Vice-Dean for Research and Internationalisation in the EMS faculty, the project reflects the faculty’s growing global presence. 

“Dr Combrink’s participation is a testament to the calibre of scholarship within the faculty,” she said. “It positions EMS as a key contributor to shaping policy and practice with societal impact.”

She added that the collaboration aligns well with the faculty’s vision for global partnerships that are rooted in local relevance.

“By focusing on contextualised evidence for policymaking, this project reflects our commitment to relevance, engagement and global partnership,” she said.

 

What comes next

Over the project’s 12-month timeline, the team will deliver:

• a case study analysis of modelling and social listening during South Africa’s COVID-19 response;
• an extended evidence mapping framework tailored to diverse evidence types;
• policy briefs and practical tools for public health practitioners; and
• a hybrid international workshop in late 2025 bringing together researchers, policymakers and health professionals to test and refine these outputs.

News Archive

Haemophilia home infusion workshop
2017-12-17


 Description: haemophilia Tags: Haemophilia, community, patient, clinical skills, training 

Parents receive training for homecare of their children with haemophilia.
Photo Supplied


Caregivers for haemophilia patients, and patients themselves from around the Free State and Northern Cape attended a home infusion workshop held by the Clinical Skills unit in the Faculty of Health Sciences in July 2017. “It felt liberating and I feel confident to give the factor to my son correctly,” said Amanda Chaba-Okeke, the mother of a young patient, at the workshop. Her son, also at the workshop, agreed. “It felt lovely and good to learn how to administer factor VIII.” 

Clinical skills to empower parents and communities

There were two concurrent sessions: one attended by doctors from the Haemophilia Treatment Centre, and the other attended by community members including factor VIII and XI recipients, caregivers and parents. The doctors’ meeting was shown informative videos and demonstrations on how to administer the newly devised factor VII and XI kit, and discussed the pressing need for trained nurses at local clinics. Dr Jaco Joubert, a haematologist, made an educational presentation to the community members.

The South African Haemophilia Foundation was represented by Mahlomola Sewolane, who gave a brief talk about the role of the organisation in relation to the condition. Meanwhile, procedural training in the simulation laboratory involved doctors and nurses helping participants to learn the procedures by using mannequins and even some volunteers from among the patients.

A medical condition causing serious complications
Haemophilia is a medical condition in which the ability of the blood to clot is severely impaired, even from a slight injury. The condition is typically caused by a hereditary lack of a coagulation factor, most often factor VIII. Usually patients must go through replacement therapy in which concentrates of clotting factor VIII (for haemophilia A) or clotting factor IX (for haemophilia B) are slowly dripped or injected into the vein, to help replace the clotting factor that is missing or low. Patients have to receive this treatment in hospital.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept